Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 13/20 | 0.41 |
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.37 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.37 |
| ▸ | MAT2A | P31153 | 1/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247927 | 0.83 | TGFBR1 (0.46) | TGFBR1MAPK14TGFBR2MAP3K20 | |
| SCHEMBL5696812 | 0.82 | TGFBR1 (0.55) | TGFBR1MAPK14TGFBR2MAP3K20 | |
| SCHEMBL3244265 | 0.81 | TGFBR1 (0.58) | TGFBR1MAPK14TGFBR2MAP3K20 | |
| SCHEMBL4035152 | 0.79 | TGFBR1 (0.49) | TGFBR1MAPK14TGFBR2MAP3K20SLC9A1 | |
| SCHEMBL5138951 | 0.78 | TGFBR1 (0.67) | TGFBR1MAPK14 | |
| SCHEMBL5696719 | 0.78 | TGFBR1 (0.45) | TGFBR1MAPK14TGFBR2MAP3K20 | |
| SCHEMBL5201166 | 0.77 | TGFBR1 (0.48) | TGFBR1TDO2MAPK14 | |
| SCHEMBL5696771 | 0.77 | TGFBR1 (0.46) | TGFBR1MAPK14TGFBR2MAP3K20 | |
| SCHEMBL6076066 | 0.76 | TGFBR1 (0.47) | TGFBR1MAPK14 | |
| SCHEMBL4030303 | 0.76 | TGFBR1 (0.39) | TGFBR1MAPK14TGFBR2MAP3K20SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958354-B2 | Pyrazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2005-10-25 | — | — | US | claimed |
| US-20100056571-A1 | NOVEL PYRAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7638537-B2 | Pyrazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2009-12-29 | — | — | US | disclosed |
| EP-1542684-B1 | NOVEL PYRAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PROD INC (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20070117850-A1 | substituted or unsubstituted 2-pyridyl moiety and a pyrozole ring substituted at 4 position with pyridine ring; inhibits the TGF-beta signaling pathway; anticancer, antifibrotic, antitumor, and antiproliferative agents | PFIZER INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-7151110-B2 | Pyrazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060025451-A1 | Novel pyrazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2006-02-02 | — | — | US | disclosed |
| US-6958354-B2 | Pyrazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2005-10-25 | — | — | US | disclosed |
| EP-1542684-A2 | NOVEL PYRAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040116474-A1 | Novel pyrazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| WO-2004026306-A2 | PYRAZOLE DERIVATIVES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025451-A1 | Novel pyrazole compounds as transforming growth factor (TGF) inhibitors | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885TDO2 3645/4885MAPK14 189/4885 |
| US-20100056571-A1 | NOVEL PYRAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885TDO2 3588/4885MAPK14 170/4885 |
| US-20070117850-A1 | substituted or unsubstituted 2-pyridyl moiety and a pyrozole ring substituted at 4 position with pyridine ring; inhibits the TGF-beta signaling pathway; anticancer, antifibrotic, antitumor, and antiproliferative agents | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885TDO2 2774/4885MAPK14 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.